Anti-inflammatory Effect of Atorvastatin in Atherosclerotic Plaques Assessed by FDG-PET Imaging

• Status: Unknown status
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether HMG-CoA reductase inhibitor, atorvastatin attenuates inflammation in atherosclerotic plaques detected by 18F-fluorodeoxyglucose(FDG) PET.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Defense Medical College, Japan
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• Subjects with accumulation of FDG-PET in carotid artery or aorta

Exclusion Criteria:

• LDL cholesterol level (calculated by using Friedewald formula) higher than 180 mg/dl or less than 120 mg/dl

• subjects currently taking HMG CoA-reductase (Statins) or fibrates

• symptomatic coronary artery diseases

• symptomatic cerebrovascular diseases

• subjects suffered from myocardial infarction or stroke within 6 months

• subjects underwent percutaneous vascular interventions or vascular operations within 6 months

• diabetic patients with poor glycemic control (HbA1c>8.5)

• hypertensive patients with poor blood pressure control

• subjects with neoplasms

• subjects with systemic inflammatory diseases